KALV News and Press, KalVista Pharmaceuticals Inc. From 02/13/24

2024-02-13 08:18:56 ET DENVER, Colo., Feb. 13, 2024 ( www.247marketnews.com )- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) reported, this morning, positive results from the phase 3 KONFIDENT clinical trial demonstrating statistically and clinically significant efficacy of sebetralstat ...

2024-02-13 07:17:05 ET More on KalVista Pharmaceticals KalVista: On Demand Oral Treatment For HAE Signifies Differentiated Advancement Seeking Alpha’s Quant Rating on KalVista Pharmaceticals Historical earnings data for KalVista Pharmaceticals Financia...

– Sebetralstat 300 mg achieved beginning of symptom relief in 1.6 hours – – Safety profile comparable to placebo – – On track for submission of new drug application to U.S. FDA in the first half of 2024 – – Conference call...

2024-01-08 10:10:17 ET More on KalVista Pharmaceticals KalVista: On Demand Oral Treatment For HAE Signifies Differentiated Advancement Seeking Alpha’s Quant Rating on KalVista Pharmaceticals For further details see: KalVista Pharmaceuticals says Venrock He...

2024-01-03 03:21:42 ET Summary Results from phase 3 KONFIDENT trial, using sebetralstat for on-demand treatment of patients with HAE, expected early 2024. Upon primary endpoint of PGI-C score being met, NDA filing of sebetralstat for HAE expected 1st half of 2024; European and Jap...

2024-01-02 10:57:55 ET More on KalVista Pharmaceticals Seeking Alpha’s Quant Rating on KalVista Pharmaceticals Historical earnings data for KalVista Pharmaceticals Financial information for KalVista Pharmaceticals For further details see: KalVista ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors today announced that data from the first report of an oral, potent, and selective FXIIa inhibitor has b...

2023-12-16 05:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

KalVista Pharmaceuticals Inc. (KALV) is expected to report $-0.71 for Q2 2024

2023-12-07 06:57:34 ET More on KalVista Pharmaceticals KalVista's Sebetralstat: A Pill Worth Swallowing In HAE Seeking Alpha’s Quant Rating on KalVista Pharmaceticals Historical earnings data for KalVista Pharmaceticals Financial information for KalVis...